.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Merck
Colorcon
Baxter
US Department of Justice
Julphar
US Army
UBS
Cantor Fitzgerald

Generated: November 18, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,910,610

« Back to Dashboard

Claims for Patent: 7,910,610

Title:Methods of administering pirfenidone therapy
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Inventor(s): Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:12/901,245
Patent Claims: 1. A method of administering pirfenidone therapy to a patient in need thereof, comprising administering to the patient a therapeutically effective amount of pirfenidone while avoiding co-administration of a strong cytochrome P450 1A2 (CYP1A2) inhibitor, wherein said patient is also in need of therapy with a strong CYP1A2 inhibitor.

2. The method of claim 1 wherein the patient has idiopathic pulmonary fibrosis (IPF).

3. The method of claim 1 wherein the therapeutically effective amount of pirfenidone is a daily dosage of 2400 mg or 2403 mg per day.

4. The method of claim 1 wherein 800 or 801 mg of pirfenidone is administered to the patient three times per day, with food.

5. A method of administering pirfenidone therapy to a patient in need thereof, comprising discontinuing administration of a strong CYP1A2 inhibitor to avoid an adverse drug interaction with pirfenidone, and administering to the patient a therapeutically effective amount of pirfenidone.

6. The method of claim 5 wherein the patient has idiopathic pulmonary fibrosis (IPF).

7. The method of claim 5 wherein the therapeutically effective amount of pirfenidone is a daily dosage of 2400 mg or 2403 mg per day.

8. The method of claim 5 wherein 800 or 801 mg of pirfenidone is administered to the patient three times per day, with food.

9. The method of claim 5 wherein the strong CYP1A2 inhibitor is discontinued within 1 month prior to starting pirfenidone therapy.

10. The method of claim 5 wherein the strong CYP1A2 inhibitor is discontinued within 2 weeks prior to starting pirfenidone therapy.

11. The method of claim 1 or 5 wherein the patient is advised that co-administration of pirfenidone with the strong CYP1A2 inhibitor can alter the therapeutic effect or adverse reaction profile of pirfenidone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
US Army
Colorcon
Chinese Patent Office
Julphar
UBS
Medtronic
Johnson and Johnson
Cantor Fitzgerald
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot